WRF Fellowships

Fellowship Overview

The Washington Research Foundation (WRF) operates at the intersection of academic research, technology development, public and private investment, philanthropy and industry. They have a strong track record of supporting innovation in the life sciences and engineering, from early research to commercialization. The WRF works with nonprofit research institutes to support a cycle of innovation that helps de-risk promising technologies while still in the institution and then invests early to support new companies spinning out from those same organizations. 

Health economics and outcomes research (HEOR) is increasingly being used at earlier stages of product development for healthcare and life sciences to inform decision making. While this expertise is commonly available at larger companies it may be unaffordable to smaller companies or academic researchers that have arguably the greatest need for that kind of service. The WRF-HEOR Fellowship aims to address this gap by providing high quality health economic and outcomes research services to WRF mission-related companies coming from qualified institutions in Washington state while also providing a valuable training activity for graduate students at Washington state research institutions. 

Fellows are paired with a Principal Investigator who is developing a novel technology in this early phase and are tasked with building an analytic framework to predict the potential value of the technology and to guide further development toward commercialization. The typical project takes about a year to complete and involves building a cost-effectiveness model, producing detailed results and projections, presenting findings to the PI and the WRF team, and preparing a final report. Fellows are also encouraged to publish their findings in peer-reviewed journals. 

Fellows & Projects 

Current Fellows

Lauren Strand, MS

  • Lauren is a PhD Candidate at the CHOICE Institute who has previous experience in cost-effectiveness modeling, policy analysis, and consulting. For her WRF Fellowship, she completed an early phase technology assessment for the Institute for Protein Design at the UW. Her work consists of a discrete event simulation to estimate costs and outcomes of currently available therapies in idiopathic pulmonary fibrosis, a rare and costly form of lung disease. She also estimated the value of a potential new therapeutic in this disease area. She is hoping to present this work at the 2020 American Thoracic Society Annual Meeting in Philadelphia. 

Samantha Clark, MS 

  • PhD Student at the CHOICE Institute.

Shuxian Chen, MA

  • PhD Candidate at the CHOICE Institute.  

He (Karen) Guo, MSc, MPP

  • PhD student at the CHOICE Institute.

Tricia Rodriguez, MPH

  • PhD Student at the CHOICE Institute

Naomi Schwartz, MS 

  • Naomi is a PhD Student at the CHOICE Institute. She is working with Professor Stephanie Berger at the UW Institute for Protein Design. Her project is a decision-analytic model designed to provide insight into the potential cost-effectiveness of a novel oral cyclic peptide treatment for Crohn’s Disease. 

Tori Dayer 

  • Tori is a Doctor of Pharmacy Student at the UW School of Pharmacy, class of 2021. Tori is working with Professor Eric Seibel to evaluate the potential value of Rapid Onsite Evaluation (ROSE), a technique used to determine the adequacy of tissue biopsy samples obtained prior to imaging and subsequent analysis for diagnostic purposes. Using a Markov model, this project seeks to determine the cost-effectiveness of a ROSE technology in varying tissue types compared to usual care. In addition, we hope to identify whether the use of ROSE technology may be more appropriate for biopsies in certain tissue types compared to others based on the typical adequacy rates and costs associated with each.

Scott Spencer, MS, MPA

  • Scott Spencer is a PhD Candidate at the UW Institute for Public Health Genetics. He is working with Dr. Erik Wambre and his team at the Benaroya Institute, who were able to identify a novel type of cell in allergy pathogenesis. Utilizing this discovery, Dr. Wambre and his team have worked to develop a novel diagnostic to identify cells that are reactive to allergens such as peanuts. This technology can identify individuals who are allergic to peanuts and eliminate the need for other potentially dangerous and costly diagnostics such as the Oral Food Challenge. The WRF peanut allergy project evaluated the cost effectiveness of various value based prices and sensitivity/specificity thresholds for this new diagnostic for children with unknown peanut allergies. Future work utilizing this diagnostic may also involve Oral Immunotherapy (OIT) that can increase individual’s tolerance for peanut ingestion, improve their quality of life, and decreased the severity and frequency of allergic reactions.

Fellowship Alumni

Kangho Suh, PharmD, PhD, Assistant Professor University of Pittsburgh.

  • Dr. Suh’s project involved estimating the potential cost-effectiveness of a hypothetical curative hepatitis B immunotherapy, similar to the recent breakthrough therapies seen in hepatitis C. He built a lifetime Markov cohort simulation model where patients cycled through a simulated disease progression of chronic hepatitis B. He also conducted threshold analyses to determine possible prices for the immunotherapy by varying willingness-to-pay and treatment effectiveness. The Technology Developers who he worked with were Edward Clark from the University of Washington and Craig Philips from Kineta, Inc. 

Application Information

New opportunities for Fellowships typically appear every two years in the spring. Check back for information on how to apply.

Contact Information

Ryan Hansen, PharmD, PhD, University of Washington Fellowship Director rhansen@uw.edu, 206.543.2402 

Marina Gano, M.Ed., University of Washington Graduate Program & Operations Manager mcgano@uw.edu, 206.616.1383 

William Canestaro, MS, PhD, Washington Research Foundation will@wrfcapital.com 206.336.5533